Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Lipid nanoparticle-mediated hit-and-run approaches yield efficient and safe in situ gene editing in human skin

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
12MB
[img]
Preview
PDF (Supporting Information) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Item Type:Article
Title:Lipid nanoparticle-mediated hit-and-run approaches yield efficient and safe in situ gene editing in human skin
Creators Name:Bolsoni, J. and Liu, D. and Mohabatpour, F. and Ebner, R. and Sadhnani, G. and Tafech, B. and Leung, J. and Shanta, S. and An, K. and Morin, T. and Chen, Y. and Arguello, A. and Choate, K. and Jan, E. and Ross, C.J.D. and Brambilla, D. and Witzigmann, D. and Kulkarni, J. and Cullis, P.R. and Hedtrich, S.
Abstract:Despite exciting advances in gene editing, the efficient delivery of genetic tools to extrahepatic tissues remains challenging. This holds particularly true for the skin, which poses a highly restrictive delivery barrier. In this study, we ran a head-to-head comparison between Cas9 mRNA or ribonucleoprotein (RNP)-loaded lipid nanoparticles (LNPs) to deliver gene editing tools into epidermal layers of human skin, aiming for in situ gene editing. We observed distinct LNP composition and cell-specific effects such as an extended presence of RNP in slow-cycling epithelial cells for up to 72 h. While obtaining similar gene editing rates using Cas9 RNP and mRNA with MC3-based LNPs (10-16%), mRNA-loaded LNPs proved to be more cytotoxic. Interestingly, ionizable lipids with a pK(a) ∼ 7.1 yielded superior gene editing rates (55%-72%) in two-dimensional (2D) epithelial cells while no single guide RNA-dependent off-target effects were detectable. Unexpectedly, these high 2D editing efficacies did not translate to actual skin tissue where overall gene editing rates between 5%-12% were achieved after a single application and irrespective of the LNP composition. Finally, we successfully base-corrected a disease-causing mutation with an efficacy of ∼5% in autosomal recessive congenital ichthyosis patient cells, showcasing the potential of this strategy for the treatment of monogenic skin diseases. Taken together, this study demonstrates the feasibility of an in situ correction of disease-causing mutations in the skin that could provide effective treatment and potentially even a cure for rare, monogenic, and common skin diseases.
Keywords:Lipid Nanoparticles, Gene Delivery, Gene Editing, Skin, ARCI, Genodermatoses, Base Editing
Source:ACS Nano
ISSN:1936-0851
Publisher:American Chemical Society
Volume:17
Number:21
Page Range:22046-22059
Date:14 November 2023
Official Publication:https://doi.org/10.1021/acsnano.3c08644
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library